Fractional exhaled nitric oxide and the peripheral blood eosinophil count as biomarkers of the response to mepolizumab in patients with severe eosinophilic asthma
المؤلفون الرئيسيون: | Shrimanker, R, Pavord, I, Price, R, Bradford, E, Keene, O, Yancey, S |
---|---|
التنسيق: | Conference item |
منشور في: |
American Thoracic Society
2018
|
مواد مشابهة
-
Prognostic and predictive value of blood eosinophil count, fractional exhaled nitric oxide and their combination in severe asthma: a post-hoc analysis
حسب: Shrimanker, R, وآخرون
منشور في: (2019) -
Evaluation of potential continuation rules for mepolizumab treatment of severe eosinophilic asthma.
حسب: Gunsoy, N, وآخرون
منشور في: (2017) -
Efficacy of add-on mepolizumab in adolescents with severe eosinophilic asthma
حسب: Steven W. Yancey, وآخرون
منشور في: (2019-09-01) -
Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
حسب: Howell, I, وآخرون
منشور في: (2024) -
Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
حسب: Bel, E, وآخرون
منشور في: (2014)